Skip to main navigation
Skip to search
Skip to main content
Luxembourg Institute of Health Home
Search content at Luxembourg Institute of Health
Home
Profiles
Research units
Research output
Projects
Equipment
Datasets
Roflumilast and cognition enhancement: A translational perspective
Jos Prickaerts
, Jill Kerckhoffs
,
Nina Possemis
, Wendy van Overveld
, Frank Verbeek
, Teun Grooters
, Anke Sambeth
, Arjan Blokland
*
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Review article
›
peer-review
16
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Roflumilast and cognition enhancement: A translational perspective'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cognition Enhancement
100%
Roflumilast
100%
Cognitive Impairment
66%
Mild Cognitive Impairment
33%
CNS Disorders
33%
Chronic Obstructive Pulmonary Disease
16%
Clinical Trials
16%
Adverse Effects
16%
Alzheimer's Disease
16%
Treatment Options
16%
Beneficial Effects
16%
Schizophrenia
16%
Cognitive Performance
16%
Rodents
16%
Vomiting
16%
Anti-inflammatory Effect
16%
Neurological Disorders
16%
Healthy Adults
16%
Patient Experience
16%
Nausea
16%
Enhancement Effect
16%
Therapeutic Window
16%
Health Burden
16%
Promising Drug
16%
Gastrointestinal Side Effects
16%
Anti-inflammatory Drugs
16%
Early Alzheimer's Disease
16%
Repurposing
16%
Healthy Elderly
16%
Impact on Daily Life
16%
Daily Functioning
16%
Cognitive Effects
16%
Neuroplasticity
16%
Financial Burden
16%
Social Burden
16%
Wide Society
16%
Phosphodiesterase 4 Inhibitor
16%
Affordable Treatment
16%
Alzheime's Disease
16%
Well Tolerated
16%
Patient Quality of Life
16%
Prodromal Stage
16%
Hemorrhage
16%
Dose-dependent
16%
Major Adverse Events
16%
Nonclinical Studies
16%
Post-stroke Cognitive Impairment
16%
Pharmacology, Toxicology and Pharmaceutical Science
Roflumilast
100%
Cognitive Defect
83%
Alzheimer's Disease
33%
Mild Cognitive Impairment
33%
Clinical Trial
16%
Normal Human
16%
Chronic Obstructive Lung Disease
16%
Antiinflammatory Activity
16%
Clinical Study
16%
Repurposing
16%
Nausea
16%
Antiinflammatory Agent
16%
Therapeutic Window
16%
Cerebrovascular Accident
16%
Central Nervous System Disease
16%
Phosphodiesterase IV Inhibitor
16%
Adverse Effect
16%